The dopamine receptor type 1 (DRD1) has been implicated in the development of hypertension in humans as well as in animal models of spontaneous hypertension. We screened the entire coding and promoter region of the human DRD1 receptor for polymorphisms to analyze their association with hypertension. The allele frequencies of two common singlenucleotide polymorphisms, AϪ48G and GϪ94A were determined in 493 hypertensive patients and 209 normotensive controls. Allele frequencies did not differ for both polymorphisms between the two groups (Ϫ48 G-allele in hypertension ϭ 0.37; Ϫ48 G-allele in normotension ϭ 0.36; Ϫ94 A-allele in hypertension ϭ 0.14; Ϫ94 A-allele in normotension ϭ 0.10). Our findings in these Caucasian patients are in contrast to a recent Japanese study that revealed a significant association of the Ϫ48 G-allele with hypertension. Thus, racial differences may play an important role concerning the association of variants in the dopamine receptor type 1 gene with essential hypertension . 
D
opamine increases renal sodium loss by diminishing sodium re-absorption in the proximal tubule. This dopamine-mediated sodium loss is smaller in hypertensive patients than in normotensive individuals, 1 and it has been linked to impaired coupling of the dopamine type 1 receptor (DRD1) and its G-protein effector enzyme complex due to gene variants in the Gprotein-coupled receptor kinase type 4.
2 Spontaneously hypertensive rats exhibit an altered dopamine receptor signal transduction in the proximal renal tubules. 3, 4 Likewise, dopamine DRD1 receptor deficient mice develop hypertension. 5 Therefore, the dopamine DRD1 receptor appears to play a role in the development of hypertension. In humans, a large study showed an association between variants of the region containing DRD1 and the ␣ 1b adrenergic receptor with systolic blood pressure (BP) variations. 6 Consistent with these findings, a recent Japanese study revealed a significant association of the G-allele of the AϪ48G human DRD1 promoter polymorphism with hypertension. 7 Several DRD1 single-nucleotide polymorphisms (SNP) have recently been analyzed in conjunction with schizophrenia, but no significant association was revealed. 8 In the present study, we screened the promoter and the coding region for polymorphisms and subsequently determined the allele frequencies of the identified SNP among Caucasian normotensive patients and hypertensive patients.
Methods

Study Population
A total of 798 Caucasian individuals were studied. Anthropometric data for the three study groups analyzed are given in Table 1 . A group of 96 unrelated individuals (medical students) was primarily used to search for polymorphisms in DRD1. Subsequently, the frequencies of genotypes were determined in 209 normotensive volunteers and 493 subjects with essential hypertension. Hypertension was defined as resting systolic BP Ͼ140 mm Hg or diastolic BP Ͼ95 mm Hg (recorded by trained nurses) or current use of antihypertensive treatment. A trained nurse measured BP on at least two separate occasions. In addition, ambulatory BP measurements (SpaceLabs Medical Inc., Redmond, WA) were performed in 331 patients.
Patients with white-coat hypertension, as demonstrated by raised clinic BP but 24-h normal ambulatory BP (Ͻ135/85 mm Hg), were not enrolled. All patients were examined thoroughly for the presence of secondary hypertension by standard clinical, laboratory, and imaging procedures. Once the presence of hypertension was established, venous blood samples were drawn for subsequent genetic analysis. Informed consent for genetic studies was obtained from each patient and control subject, and the study was approved by two ethical committees.
Genotyping
Genomic DNA was prepared from peripheral white blood cells using a standard technique (Qiagen, Hilden, Germany).
Using the published sequence of human DRD1, 9 primers were designed to amplify 16 overlapping fragments covering the entire coding and the promoter region. Genomic DNA of 96 healthy control subjects (unrelated population) was used to search for polymorphisms by polymerase chain reaction (PCR) and single strand conformation polymorphism analysis (SSCP). The PCR amplification was carried out in 25-L volume containing 2 ng genomic DNA, 10 mol/L of each primer, 2,5 L MgCl 2 , 10 mol/L of each dNTP, and 1U AmpliTaq Gold-polymerase (PE Applied Biosystems, Foster City, CA). The PCR was performed initially for 12 min at 95°C; followed by 40 cycles, each with 30 sec at 95°C, 30 sec at 58°to 68°C (depending on primer sequence), 30 sec at 72°C, and final elongation of 5 min at 72°C. For SSCP, 8 L of the PCR product was mixed with 20 L of denaturating solution (85% formamid, 20 mmol/L NaOH , 0.01% xylene xyanole FF, 0.001% bromphenole blue, and 25 mmol/L EDTA) and was denatured for 2 min at 95°C. Samples were chilled quickly on ice and loaded onto a 12% polyacrylamide gel. All PCR fragments revealing aberrant mobility were sequenced directly in both directions on an ABI 373 fluorescence sequencer using big dye terminator chemistry (PE Applied Biosystems, Foster City, CA).
To determine the genotypic distribution, we used restriction fragment length polymorphism analysis (RFLP) of the respective PCR products of 702 hypertensive and normotensive subjects at the polymorphic loci G-94A (restriction enzyme BstNI) and AϪ48G (DdeI).
Statistical Analysis
All data are presented as means Ϯ SD or as proportions. Continuous variables were compared by two-sided Student t test or the non-parametric Kruskal-Wallis test for independent samples as appropriate, and categorical data were assessed by 2 statistics. The relationship between both genotypes and BP were examined by step-wise multiple regression analysis using gender, age, duration of therapy, and body mass index as covariates using SPSS for Windows, release 11.5 (SPSS Inc., Chicago, IL). A value of P Ͻ .05 was considered to be statistically significant.
Results
We identified seven polymorphic loci within DRD1 in a group of 96 medical students of Caucasian origin. The positions of the polymorphic loci and their allele frequencies correspond to those identified for Caucasians in previous studies 8, 10 ( Table 2 ). The genotype distribution and allele frequencies of the two common SNP, AϪ48G and GϪ94A in the DRD1 promoter region were determined in 493 hypertensive patients and 209 normotensive control subjects ( Table 3 ). The respective allele frequencies did not differ for both polymorphisms between the two groups. Hardy-Weinberg equilibrium was fulfilled in the control and case subjects at the AϪ48G locus and in control subjects at the GϪ94A locus. At this locus, the hypertensive population departed from Hardy-Weinberg equilibrium because of the detection of seven more than expected homozygous AA hypertensive cases ( 2 ϭ 6.99, P ϭ .05). In the sample of hypertensive and normotensive control subjects, anthropometric parameters, ambulatory BP and resting BP values (Table 1) , and number of antihypertensive drugs (data not shown) did not differ between genotypic groups. However, the average age of the normotensive control group was lower than in the hypertensiveg group. Multivariate regression using age and duration of hypertension, together with gender and BMI as covariates, showed no association of either locus with BP.
Discussion
In this study, we identified several of the previously described variants of the DRD1 gene. None of these polymorphisms, including the previously implicated promoter polymorphisms at positions Ϫ48 and Ϫ94, were associated with the risk or severity of hypertension in our Caucasian cohort.
Our findings are in contrast to those of Sato et al, 7 who observed in Japanese hypertensive individuals (n ϭ 131) a higher frequency of the Ϫ48G-allele than in normotensive Japanese persons (n ϭ 136). However, the frequency of the Ϫ48G-allele was twofold higher in our Caucasian study group than in the Japanese group (frequency of the A-allele in German (Berlin) hypertensive subjects ϭ 0.37 versus Japanese hypertensive subjects ϭ 0.16; P Ͻ .05). Our findings thus may underline the importance of racial differences as a determinant of genetic variation when studying the potential role of genetic risk factors in complex diseases such as hypertension.
Some limitations of our study and of the difference in the Japanese results have to be addressed. We cannot completely rule out a biological effect of the DRD1 SNP, because negative results have to be powered by large populations to reach statistical significance. However, assuming 5 mm Hg as a clinically relevant difference in BP between homozygotes for the Ϫ48G variant, our study has a power of 0.7 to detect such a difference. The power to detect a difference of 10 mm Hg is 0.99. It is therefore very unlikely that a large influence of these genetic markers on BP was missed. On the other hand, the positive result of the Japanese study at the AϪ48G locus has a power of 0.81 (P ϭ .05) and was found in a population of 131 hypertensive and 136 normotensive individuals. Thus, it is conceivable that the positive findings of the Japanese study and the difference in our results may have been found by chance. Concerning the Ϫ95 locus, it must be stressed that the power is lower than the Ϫ48 locus because of the asymmetric genotype distribution with a small number of minor allele homozygous (AA) control and hypertensive subjects. Positive associations with hypertension at this locus have not yet been described and may be difficult to detect. That phenomenon is present in all studies dealing with an asymmetric genotype distribution and may have led to departure from Hardy-Weinberg equilibrium detected in the hypertensive group.
In conclusion, our study does not support the hypothesis that genetic variants of the DRD1 gene are important risk markers of hypertension in Caucasians. Differences from previous observations in Japanese hypertensive individuals may be related to racial differences between Japanese and Caucasian subjects.
